医药界盛会的“整岁生日”为何落地南京江北？“这里有更多合作机会和想象空间！”

Core Insights - The 10th Pharmaceutical Innovation and Investment Conference has commenced in Nanjing, attracting nearly a thousand participants from academia, industry, and investment sectors, including leaders from renowned pharmaceutical companies [1][2] - The conference serves as a platform to explore global pharmaceutical innovation trends and has become a "barometer" for pharmaceutical innovation and investment in China since its inception in 2016 [1][2] Group 1: Conference Highlights - The conference features various sub-forums focusing on cutting-edge topics such as anti-tumor new drugs, gene and cell therapy, and AI in pharmaceutical research, along with discussions on commercial insurance and healthcare payment reforms [2] - A special session, "Nanjing Jiangbei New Area-Hong Kong Biopharmaceutical Industry Exchange Conference," facilitates in-depth discussions between Hong Kong representatives and local enterprises [2] Group 2: Industry Development - The Jiangbei New Area is emerging as a vibrant hub for the biopharmaceutical industry, with over 1,300 biopharmaceutical companies and a competitive ranking of 8th nationwide [3] - The area has seen significant achievements, including 402 listed drugs and 1,261 medical device products, with several innovative products being first in the world [3] - The local biopharmaceutical sector is attracting attention from the capital market, with multiple companies, including Yaojie Ankang and Weili Zhibo, recently listing on the Hong Kong Stock Exchange [3][4] Group 3: Future Opportunities - The choice of Jiangbei New Area as the conference venue reflects the growing number of projects and enterprises in the region, which is also home to the first national university technology transfer center for biomedicine [5] - The presence of industry leaders at the conference is expected to inject confidence and vitality into the local biopharmaceutical ecosystem, paving the way for new collaborations and projects [5]